Animal studies show that astatine, similarly to iodine – although to a lesser extent, perhaps because of its slightly more metallic nature  – is preferentially (and dangerously) concentrated in the thyroid gland. Unlike iodine, astatine also shows a tendency to be taken up by the lungs and spleen, possibly because of in-body oxidation of At– to At+. If administered in the form of a radiocolloid it tends to concentrate in the liver. Experiments in rats and monkeys suggest that astatine-211 causes much greater damage to the thyroid gland than does iodine-131, with repetitive injection of the nuclide resulting in necrosis and cell dysplasia within the gland. Early research suggested that injection of astatine into female rodents caused morphological changes in breast tissue; this conclusion remained controversial for many years. General agreement was later reached that this was likely caused by the effect of breast tissue irradiation combined with hormonal changes due to irradiation of the ovaries. Trace amounts of astatine can be handled safely in fume hoods if they are well-aerated; biological uptake of the element must be avoided.